eCite Digital Repository

Effects of heparin and enoxaparin on APP processing and Aβ production in primary cortical neurons from Tg2576 mice


Cui, H and Hung, AC and Klaver, DW and Suzuki, T and Freeman, C and Narkowicz, C and Jacobson, GA and Small, DH, Effects of heparin and enoxaparin on APP processing and Aβ production in primary cortical neurons from Tg2576 mice, PLoS One, 6, (7) Article e23007. ISSN 1932-6203 (2011) [Refereed Article]

Restricted - Request a copy

Copyright Statement

Copyright © 2010 (Cui, H) et al. This work is distributed under the Creative Commons XXXXXXX XXXX License.

Official URL:

DOI: doi:10.1371/journal.pone.0023007


Background: Alzheimer’s disease (AD) is caused by accumulation of Aβ, which is produced through sequential cleavage of b-amyloid precursor protein (APP) by the β-site APP cleaving enzyme (BACE1) and γ-secretase. Enoxaparin, a low molecular weight form of the glycosaminoglycan (GAG) heparin, has been reported to lower Aβ plaque deposition and improve cognitive function in AD transgenic mice.

Methodology/Principal Findings: We examined whether heparin and enoxaparin influence APP processing and inhibit Aβ production in primary cortical cell cultures. Heparin and enoxaparin were incubated with primary cortical cells derived from Tg2576 mice, and the level of APP and proteolytic products of APP (sAPPα, C99, C83 and Aβ) was measured by western blotting. Treatment of the cells with heparin or enoxaparin had no significant effect on the level of total APP. However, both GAGs decreased the level of C99 and C83, and inhibited sAPPα and Aβ secretion. Heparin also decreased the level of β-secretase (BACE1) and α-secretase (ADAM10). In contrast, heparin had no effect on the level of ADAM17.

Conclusions/Significance: The data indicate that heparin and enoxaparin decrease APP processing via both α- and β-secretase pathways. The possibility that GAGs may be beneficial for the treatment of AD needs further study.

Item Details

Item Type:Refereed Article
Keywords:Alzheimer's disease
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacology and therapeutics
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Cui, H (Mr Hao Cui)
UTAS Author:Hung, AC (Dr Amos Hung)
UTAS Author:Klaver, DW (Mr David Klaver)
UTAS Author:Narkowicz, C (Dr Christian Narkowicz)
UTAS Author:Jacobson, GA (Professor Glenn Jacobson)
UTAS Author:Small, DH (Professor David Small)
ID Code:72764
Year Published:2011
Web of Science® Times Cited:15
Deposited By:Pharmacy
Deposited On:2011-08-31
Last Modified:2018-03-28

Repository Staff Only: item control page